Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective

Current Pharmaceutical Design

Volumn 22, Issue 21, 2016, Pages 3171-3181

  Zhang, Wenjuan ^a   Bai, Yaofei ^a   Wang, Yonghua ^a   Xiao, Wei ^b  

^a NORTHWEST A F UNIVERSITY   (China)

^b State Key Laboratory of New tech for Chinese Medicine Pharmaceutical Process   (China)

Author keywords

Drug combination; Drug design; Drug repurposing; Multi target drugs; Network pharmacology; Polypharmacology

Indexed keywords

ARTICLE; COMBINATION DRUG THERAPY; DRUG EFFICACY; DRUG INDICATION; DRUG REPOSITIONING; DRUG TARGETING; GENE REGULATORY NETWORK; GENETIC DISORDER; HUMAN; POLYPHARMACOLOGY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; DRUG DEVELOPMENT;

DRUG DISCOVERY; HUMANS; POLYPHARMACOLOGY;

EID: 84975778520     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160224142812     Document Type: Article

References (142)

1. Peters J-U, Hert J, Bissantz C, et al. Can we discover pharmacological promiscuity early in the drug discovery process? Drug Discov Today 2012; 17(7): 325-35.
2. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112(13): 4808-17.
3. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. New Engl J Med 2010; 363(9): 809-19.
4. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New Engl J Med 2006; 355(26): 2733-43.
5. Szuromi P, Vinson V, Marshall E. Rethinking drug discovery. Science 2004; 303(5665): 1795.
6. Editorial office. Bigger isn’t always better. Nature 2002; 418: 353.
7. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008; 4(11): 682-90.
8. Apsel B, Blair JA, Gonzalez B, et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol 2008; 4(11): 691-9.
9. Rosini M. Polypharmacology: the rise of multitarget drugs over combination therapies. Future Med Chem 2014; 6(5): 485-7.
10. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004; 3(4): 353-9.
11. Paolini GV, Shapland RH, van Hoorn WP, et al. Global mapping of pharmacological space. Nat Biotechnol 2006; 24(7): 805-15.
12. Boran AD, Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Dev 2010; 13(3): 297-309.
13. Lounkine E, Keiser MJ, Whitebread S, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012; 486(7403): 361-7.
14. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010; 10(2): 130-7.
15. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9(1): 28-39.
16. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nature Rev Drug Discov 2005; 4(5): 387-98.
17. Wang X, Hu J, She Y, et al. Cortical PKC inhibition promotes axonal regeneration of the corticospinal tract and forelimb functional recovery after cervical dorsal spinal hemisection in adult rats. Cereb Cortex 2014; 24(11): 3069-79.
18. Reddy AS, Zhang S. Polypharmacology: drug discovery for the future. Expert Rev Clin Phar 2013; 6: 41-7.
19. Xie L, Xie L, Bourne PE. Structure-based systems biology for analyzing off-target binding. Curr Opin Struct Biol 2011; 21(2): 189-99.
20. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994; 264(5157): 375-82.
21. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2(3): 225.
22. Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery. J Med Chem 2014; 57(19): 7874-87.
23. Frantz S. Drug discovery: playing dirty. Nature 2005; 437(7061): 942-3.
24. Mencher SK, Wang LG. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin Phar 2005; 5(1): 3.
25. Dixon SJ, Stockwell BR. Identifying druggable disease-modifying gene products. Curr Opin Chem Biol 2009; 13(5): 549-55.
26. Simon Z, Peragovics Á, Vigh-Smeller M, et al. Drug effect prediction by polypharmacology-based interaction profiling. J Chem Inf Model 2011; 52(1): 134-45.
27. Campillos M, Kuhn M, Gavin A-C, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 2008; 321(5886): 263-66.
28. Peters J-U. Polypharmacology-foe or friend? J Med Chem 2013; 56(22): 8955-71.
29. Nolan GP. What's wrong with drug screening today. Nat Chem Biol 2007; 3(4): 187-91.
30. Bottegoni G, Favia AD, Recanatini M, Cavalli A. The role of fragment-based and computational methods in polypharmacology. Drug Discov Today 2012; 17(1): 23-34.
31. Rather MA, Bhat BA, Qurishi MA. Multicomponent phytotherapeutic approach gaining momentum: Is the “one drug to fit all” model breaking down? Phytomedicine 2013; 21(1): 1-14.
32. Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 2010; 16(16): 4094-104.
33. Borisy AA, Zimmermann GR, Lehár J. Multicomponent therapeutics. Polyphar in Drug Discov 2012: 315-21.
34. Monzon JG, Dancey J. Combination agents versus multi-targeted agents-pros and cons. In: Shahid M, Hornberg J, Eds. Designing Multi-Target Drugs.1st ed. London: Royal Shakespeare Country Publishing Press 2012; pp: 155-80.
35. Evans B, Rittle K, Bock M, et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem 1988; 31(12): 2235-46.
36. Manley PW, Zimmermann J. Drug research leading to imatinib and beyond to nilotinib. Polyphar Drug Discov 2012: 409-21.
37. Schutz FA, Choueiri TK, Sternberg CN. Pazopanib: Clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol 2011; 77(3): 163-71.
38. Di Lorenzo G, Buonerba C, Biglietto M, et al. The therapy of kidney cancer with biomolecular drugs. Cancer Treat Rev 2010; 36(Suppl 3): S16-20.
39. Petrelli A. Polypharmacological kinase inhibitors: new hopes for cancer therapy. Polyphar Drug Discov 2012: 149-65.
40. Bukowski RM, Yasothan U, Kirkpatrick P. Pazopanib. Nat Rev Drug Discov 2010; 9(1): 17-8.
41. Roth BL, Sheffler D, Potkin SG. Atypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’? Clin Neuro Sci Res 2003; 3(1): 108-17.
42. Lipton SA. Turning down, but not off. Nature 2004; 428(6982): 473.
43. Rogawski M. Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents-toward an understanding of their favorable tolerability. Amino Acids 2000; 19(1): 133-49.
44. Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005, 26(4): 178-82.
45. Aube J. Drug repurposing and the medicinal chemist. ACS Med Chem Lett 2012; 3(6): 442-4.
46. Chong CR, Sullivan DJ, Jr. New uses for old drugs. Nature 2007; 448(7154): 645-6.
47. Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature 2009; 462(7270): 175-81.
48. Ekins S, Williams AJ, Krasowski MD, Freundlich JS. In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today 2011; 16(7): 298-310.
49. Gupta SC, Sung B, Prasad S, Webb LJ, Aggarwal BB. Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci 2013; 34(9): 508-17.
50. Oprea TI, Bauman JE, Bologa CG, et al. Drug repurposing from an academic perspective. Drug Discov Today Ther Stratgies 2011; 8(3): 61-9.
51. Surviladze Z, Young SM, Sklar LA. High-throughput flow cytometry bead-based multiplex assay for identification of Rho GTPase inhibitors. Methods Mol Biol 2012; 827: 253-70.
52. Wang X, Wei X, Bram TJ, et al. Three-dimensional reconstruction of protein networks provides insight into human genetic disease. Nat. Biotechnol. 2012; 30(2), 159-64.
53. Coombes RC, Perez D, Gazet J-C, Ford H, Powles TJ. Danazol treatment for advanced breast cancer. Cancer Chemoth Pharm 1983; 10(3): 194-95.
54. Gennari L, Merlotti D, Paola VD, Nuti R. Raloxifene in breast cancer prevention. Expert Opin Drug Saf 2008, 259-70.
55. Duenas-Gonzalez A, Garcia-Lopez P, Herrera LA, et al. The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer 2008; 7(1): 82.
56. Bundscherer A, Hafner C. Breathing new life into old drugs: indication discovery by systems directed therapy. In: Albrecht R, Ed. From Molecular to Modular Tumor Therapy. 1st ed. Verlag: Springer Press 2010; pp. 483-503.
57. Dudley JT, Deshpande T, Butte AJ. Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform 2011; 12: 303-11.
58. Gottlieb A, Stein GY, Ruppin E, Sharan R. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol 2011; 7(1): 496.
59. Lee SH, Oshige M, Durant ST, et al. The SET domain protein Metnase mediates foreign DNA integration and links integration to nonhomologous end-joining repair. Proc Natl Acad Sci USA 2005; 102(50): 18075-80.
60. Allen C, Ashley AK, Hromas R, Nickoloff JA. More forks on the road to replication stress recovery. J Mol Cell Biol 2011; 3(1): 4-12.
61. Ohlow MJ, Moosmann B. Phenothiazine: the seven lives of pharmacology's first lead structure. Drug Discov Today 2011; 16(3): 119-31.
62. Coombes R C, Perez D, Gazet J C, et al. Danazol treatment for advanced breast cancer. Cancer Chemother Pharmacol 1983; 10(3): 194-5.
63. Gennari L, Merlotti D, Paola V D, et al. Raloxifene in breast cancer prevention. Expert Opin Drug Saf 2008; 7(3): 259-70.
64. Dai Y, Qiao L, Chan KW, et al. Loss of XIAP sensitizes rosiglitazone-induced growth inhibition of colon cancer in vivo. Int J Cancer 2008; 122: 2858-63.
65. Takano S, Kubota T, Nishibori H, et al. Pioglitazone, a ligand for peroxisome proliferator-activated receptor-γ acts as an inhibitor of colon cancer liver metastasis. Anticancer Res 2008; 28(6A): 3593-9.
66. Kulke M H, Demetri G D, Sharpless N E, et al. A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy_resistant metastatic colorectal cancer. J Cancer 2002; 8(5): 395-9.
67. Zaslau S, Riggs D R, Jackson B J, et al. In vitro effects of pentosan polysulfate against malignant breast cells. Am J Surg 2004; 188(5): 589-92.
68. Csermely P, Korcsmáros T, Kiss HJ, London G, Nussinov R. Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol Ther 2013; 138(3): 333-408.
69. Reaume AG. Drug repurposing through nonhypothesis driven phenotypic screening. Drug Discov Today: Ther Strategies 2012; 8(3): 85-8.
70. Lussier YA, Chen JL. The emergence of genome-based drug repositioning. Sci Transl Med 2011; 3(96): 96ps35.
71. Padhy BM, Gupta YK. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med 2011; 57(2): 153-60.
72. Lamb J. The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 2007; 7(1): 54-60.
73. Sirota M, Dudley JT, Kim J, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 2011; 3(96): 96ra77.
74. Josset L, Textoris J, Loriod B, et al. Gene expression signaturebased screening identifies new broadly effective influenza a antivirals. PLoS One 2010(10); 5: e13169.
75. Stuart JM, Segal E, Koller D, Kim SK. A gene-coexpression network for global discovery of conserved genetic modules. Science 2003; 302(5643): 249-55.
76. Bergmann S, Ihmels J, Barkai N. Similarities and differences in genome-wide expression data of six organisms. PLoS Biol 2004; 2(1): E9.
77. Li P, Fu Y, Wang Y. Network based approach to drug discovery: a mini review. Mini-Rev Med Chem 2015; 15(8): 687-95.
78. Kim TY, Kim HU, Lee SY. Data integration and analysis of biological networks. Curr Opin Biotechnol 2010; 21(1): 78-84.
79. Salentin S, Haupt VJ, Daminelli S, Schroeder M. Polypharmacology rescored: Protein-ligand interaction profiles for remote binding site similarity assessment. Prog Biophys Mol Biol 2014; 116(2): 174-86.
80. Mestres J, Gregori-Puigjané E, Valverde S, Solé RV. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol BioSyst 2009; 5(9): 1051-7.
81. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M. Drugtarget network. Nat Biotechnol 2007; 25(10): 1119-26.
82. Butina D, Segall MD, Frankcombe K. Predicting ADME properties in silico: methods and models. Drug Discov Today 2002; 7(11): S83-8.
83. Byvatov E, Fechner U, Sadowski J, Schneider G. Comparison of support vector machine and artificial neural network systems for drug/nondrug classification. J Chem Inf Comp Sci 2003; 43(6): 1882-9.
84. Cheng AC, Coleman RG, Smyth KT, et al. Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 2007; 25(1): 71-5.
85. Donald BR. Algorithms in structural molecular biology. In: Bruce RD Eds. Computational Molecular Biology. 1st ed. Cambridge: MIT Press 2011.
86. Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and Auto-DockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009; 30(16): 2785-91.
87. Rognan D. Chemogenomic approaches to rational drug design. Br J Pharmacol 2007; 152(1): 38-52.
88. Stockwell BR. Chemical genetics: ligand-based discovery of gene function. Nat Rev Genet 2000; 1(2): 116-25.
89. Kanehisa M, Goto S, Hattori M, et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006; 34(suppl 1): D354-7.
90. Grinter SZ, Liang Y, Huang SY, Hyder SM, Zou X. An inverse docking approach for identifying new potential anti-cancer targets. J Mol Graph Model 2011; 29(6): 795-9.
91. Hui-fang L, Qing S, Jian Z, Wei F. Evaluation of various inverse docking schemes in multiple targets identification. J Mol Graph Model 2010; 29(3): 326-30.
92. Chen Y, Zhi D. Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Prot Struct Funct Bioinform 2001; 43(2): 217-26.
93. Takigawa I, Tsuda K, Mamitsuka H. Mining significant substructure pairs for interpreting polypharmacology in drug-target network. PloS one 2011; 6(2): e16999.
94. Simon Z, Vigh-Smeller M, Peragovics Á, et al. Relating the shape of protein binding sites to binding affinity profiles: is there an association? BMC Struct Biol 2010; 10(1): 32.
95. Nigsch F, Bender A, Jenkins JL, Mitchell JB. Ligand-target prediction using Winnow and naive Bayesian algorithms and the implications of overall performance statistics. J Chem Inf Model 2008; 48(12): 2313-25.
96. Niijima S, Yabuuchi H, Okuno Y. Cross-target view to feature selection: identification of molecular interaction features in ligandtarget space. J Chem Inf Model 2010; 51(1): 15-24.
97. Perez-Nueno VI, Karaboga AS, Souchet M, Ritchie DW. GES polypharmacology fingerprints: a novel approach for drug repositioning. J Chem Inf Model 2014; 54(3): 720-34.
98. Hopkins AL. Network pharmacology. Nat Biotechnol 2007; 25(10): 1110-1.
99. Huang C, Zheng C, Li Y, Wang Y, Lu A, Yang L. Systems pharmacology in drug discovery and therapeutic insight for herbal medicines. Brief Bioinform 2014; 15(5): 710-33.
100. Grippo AJ, Johnson AK. Biological mechanisms in the relationship between depression and heart disease. Neurosci Biobehav Rev 2002; 26(8): 941-62.
101. Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005; 26(4): 178-82.
102. Tao W, Xu X, Wang X, et al. Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J Ethnopharmacol 2013; 145(1): 1-10.
103. Li X, Xu X, Wang J, et al. A system-level investigation into the mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for cardiovascular disease treatment. PLoS One 2012; 7(9): e43918.
104. Liu H, Wang J, Zhou W, Wang Y, Yang L. Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice. J Ethnopharmacol 2013; 146(3): 773-93.
105. Jeong H, Mason SP, Barabasi AL, Oltvai ZN. Lethality and centrality in protein networks. Nature 2001; 411(6833): 41-2.
106. Ivanic J, Yu X, Wallqvist A, Reifman J. Influence of protein abundance on high-throughput protein-protein interaction detection. PLoS One 2009; 4(6): e5815.
107. Yu H, Braun P, Yildirim MA, et al. High-quality binary protein interaction map of the yeast interactome network. Science 2008; 322(5898): 104-10.
108. Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M. The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS Comput Biol 2007; 3(4): e59.
109. Yu H, Zhu X, Greenbaum D, Karro J, Gerstein M. TopNet: a tool for comparing biological sub-networks, correlating protein properties with topological statistics. Nucleic Acids Res 2004; 32(1): 328-37.
110. Goh KI, Cusick ME, Valle D, et al. The human disease network. Proc Natl Acad Sci USA 2007; 104(21): 8685-90.
111. Franke L, Van Bakel H, Fokkens L, et al. Reconstruction of a functional human gene network, with an application for prioritizing positional candidate genes. Am J Hum Genet 2006; 78(6): 1011-25.
112. Vidal M, Cusick ME, Barabasi AL. Interactome networks and human disease. Cell 2011; 144(6): 986-98.
113. Wachi S, Yoneda K, Wu R. Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics 2005; 21(23): 4205-8.
114. Jonsson PF, Bates PA. Global topological features of cancer proteins in the human interactome. Bioinformatics 2006; 22(18): 2291-7.
115. Marcotte EM, Pellegrini M, Ng HL, et al. Detecting protein function and protein-protein interactions from genome sequences. Science 1999; 285(5428): 751-3.
116. Oti M, Snel B, Huynen MA, Brunner HG. Predicting disease genes using protein-protein interactions. J Med Genet 2006; 43(8): 691-8.
117. Chen B, Wild D, Guha R. PubChem as a source of polypharmacology. J Chem Inf Model 2009; 49(9): 2044-55.
118. Gong Y, Zhang Z. Alternative signaling pathways: When, where and why? FEBS Lett 2005; 579(24): 5265-74.
119. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321(5897): 1801-6.
120. Korcsmáros T, Szalay MS, Böde C, Kovács IA, Csermely P. How to design multi-target drugs: target search options in cellular networks. Expert Opin Drug Dis 2007, 2: 1-10.
121. Liu KQ, Liu ZP, Hao JK, Chen L, Zhao XM. Identifying dysregulated pathways in cancers from pathway interaction networks. BMC Bioinformatics 2012; 13(1): 126.
122. Zhao S, Li S. Network-based relating pharmacological and genomic spaces for drug target identification. PloS one 2010; 5(7): e11764.
123. Wu X, Jiang R, Zhang MQ, Li S. Network-based global inference of human disease genes. Mol Syst Biol 2008; 4(1): 189.
124. Altieri DC. Mitochondrial Hsp90 chaperones as novel molecular targets in prostate cancer. Future Oncol 2010; 6(4): 487.
125. Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr Opin Struct Biol 2006; 16(1): 127-36.
126. Dar AC, Das TK, Shokat KM, Cagan RL. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 2012; 486(7401): 80-4.
127. Milletti F, Vulpetti A. Predicting polypharmacology by binding site similarity: from kinases to the protein universe. J Chem Inf Model 2010; 50(8): 1418-31.
128. Jorgensen WL. The many roles of computation in drug discovery. Science 2004; 303 (5665): 1813-8.
129. DeGraw AJ, Keiser MJ, Ochocki JD, Shoichet BK, Distefano MD. Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs. J Med Chem 2010; 53(6): 2464-71.
130. Keiser MJ, Roth BL, Armbruster BN, et al. Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007; 25(2): 197-206.
131. Moneriz C, Mestres J, Bautista JM, Diez A, Puyet A. Multi_targeted activity of maslinic acid as an antimalarial natural compound. FEBS J 2011; 278(16): 2951-61.
132. Mestres J, Seifert S, Oprea T. Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndrome. Clin Phar Ther 2011; 90(5): 662-5.
133. Kolb P, Rosenbaum DM, Irwin JJ, et al. Structure-based discovery of _2-adrenergic receptor ligands. Proc Natl Acad Sci USA 2009; 106(16): 6843-8.
134. Gregori-Puigjané E, Setola V, Hert J, et al. Identifying mechanismof-action targets for drugs and probes. Proc Natl Acad Sci USA 2012; 109(7403): 11178-83.
135. Schneider G, Fechner U. Computer-based de novo design of druglike molecules. Nat Rev Drug Discov 2005; 4(8): 649-63.
136. Jalencas X, Mestres J. Chemoisosterism in the Proteome. J Chem Inf Model 2013; 53(2): 279-92.
137. Morphy R, Rankovic Z. Fragments, network biology and designing multiple ligands. Drug Discov Today 2007; 12(3): 156-60.
138. Jalencas X, Mestres J. On the origins of drug polypharmacology. Med Chem Comm 2013; 4(1): 80-7.
139. Nobeli I, Favia AD, Thornton JM. Protein promiscuity and its implications for biotechnology. Nat Biotechnol 2009; 27(2): 157-67.
140. Jenwitheesuk E, Horst JA, Rivas KL, Van Voorhis WC, Samudrala R. Novel paradigms for drug discovery: computational multitarget screening. Trends Pharmacol Sci 2008; 29(2): 62-71.
141. Janga SC, Tzakos A. Structure and organization of drug-target networks: insights from genomic approaches for drug discovery. Mol Biosyst 2009; 5(12): 1536-48.
142. Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov Today 2005; 10(2): 139-47.